Wells Fargo & Company Arvinas, Inc. Put Options Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ARVN
# of Institutions
224Shares Held
68.7MCall Options Held
166KPut Options Held
31.3K-
Eco R1 Capital, LLC San Francisco, CA6.73MShares$170 Million6.33% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.67MShares$169 Million0.0% of portfolio
-
Black Rock Inc. New York, NY6.26MShares$158 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.99MShares$101 Million0.01% of portfolio
-
Avidity Partners Management LP Dallas, TX2.99MShares$75.7 Million3.91% of portfolio
About ARVINAS, INC.
- Ticker ARVN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,205,300
- Market Cap $1.35B
- Description
- Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor ...